Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific begins enrolment for Vercise patient registry

Boston Scientific begins enrolment for Vercise patient registry

15th April 2014

Boston Scientific has announced the commencement of enrolment for a new clinical registry of its Vercise deep brain stimulation (DBS) system.

It has already enrolled the first patient in the registry, which will evaluate clinical outcomes and the economic value of the Vercise system in patients with Parkinson's disease. The multi-centre prospective study is expected to enroll up to 300 patients at leading hospitals internationally.

Vercise is an implantable medical device designed to selectively stimulate targeted areas in the brain, enabling customised therapy and helping improve quality of life for Parkinson's patients.

A preliminary assessment of the previous Vantage study demonstrated a mean improvement in motor function among 62.4 percent of Parkinson's patients at six months post implant with Vercise.

Maulik Nanavaty, president of neuromodulation at Boston Scientific, said: "This registry will enable us to provide physicians with a comprehensive, long-term view of real-world experience and results with the Vercise DBS System for the many patients affected by Parkinson's disease."

This comes after Vercise was granted European CE Mark approval for the treatment of dystonia towards the end of last year.ADNFCR-8000103-ID-801712772-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.